Fri Nov 15 14:35:44 IST 2024: ## UK to Trial Weight-Loss Drugs to Combat Unemployment

**Manchester, UK** – In a bid to tackle the UK’s unemployment crisis, the government is launching a five-year trial using weight-loss drugs, such as Mounjaro and Zepbound, manufactured by US pharmaceutical giant Eli Lilly. The trial, announced by UK Health Minister Wes Streeting, will take place in Greater Manchester and involve approximately 3,000 residents.

The initiative follows a recent summit hosted by Prime Minister Keir Starmer to encourage investment in the UK, where Eli Lilly pledged £279 million ($365.4m) in investment. While the details of this investment remain unclear, the weight-loss drug trial represents a significant step in exploring the potential link between obesity and unemployment.

The study aims to observe the long-term effects of these drugs on participants, with the hope that weight loss will lead to improved health and increased employment opportunities.

The trial is based on the theory that obesity contributes to economic inactivity. While there is no direct causal link proven, studies have shown a correlation between unemployment and obesity, with longer periods of unemployment increasing the likelihood of obesity.

The UK faces a significant obesity problem with 25.9% of adults classified as obese and another 37.9% overweight. The NHS currently spends £11 billion ($14bn) annually on obesity-related health issues.

Weight-loss drugs like Mounjaro and Zepbound work by suppressing appetite through mimicking the hormone GLP-1. They are typically prescribed for individuals with diabetes but have also shown promising results for weight loss.

While experts remain cautious about the direct impact of these drugs on employment, the trial represents a unique approach to tackling a complex issue. The government hopes to demonstrate that investment in weight-loss medication could ultimately benefit the UK economy through increased productivity and reduced healthcare costs.

However, critics argue that the trial is premature and overlooks other factors contributing to unemployment.

The trial’s findings will be closely watched as it could potentially influence future healthcare policies and the use of weight-loss drugs in tackling unemployment globally.

Read More